Sanofi and GlaxoSmithKline The pharmaceutical industry is likely to benefit from climate change as increasing temperatures are expected to result in a rise in the number of diseases spread by humans , such as mosquitoes and fleas , thereby increasing demand for vaccines , according to a report from Morgan Stanley . The report singled out the mosquitoes Aedes aegypti and Circus albopictus in particular and predicted Australia as the most affected country . The report estimated that $ 50bn to $ 125bn of vaccines will be needed to cover the extra exposure , with Sanofi and GlaxoSmithKline likely to benefit the most due to their pipelines for tropical disease drugs .
The pharmaceutical industry is likely to benefit from climate change as increasing temperatures are expected to result in a rise in the number of diseases spread by humans , such as mosquitoes and fleas , thereby increasing demand for vaccines , according to a report from Morgan Stanley . The report singled out the mosquitoes Aedes aegypti and Circus albopictus in particular and predicted Australia as the most affected country . The report estimated that $ 50bn to $ 125bn of vaccines will be needed to cover the extra exposure , with Sanofi and GlaxoSmithKline likely to benefit the most due to their pipelines for tropical disease drugs .